Fig. 2.

Disease-specific survival (in months) of ovarian cancer patients based on tumor-infiltrating lymphocytes. Cumulative survival time was estimated by the Kaplan–Meier method. Log Rank test was used to evaluate survival differences between groups. High numbers of CD8⁺ T-lymphocytes (a) and a high CD8⁺/Foxp3⁺ ratio (b) in ovarian-derived tumor tissue were associated with improved survival in FIGO stage I–IV disease. In advanced stage patients, a survival benefit was observed for patients with CD45R0⁺ T-lymphocytes (c) CD8⁺ T-lymphocytes (d), FoxP3⁺ T-lymphocytes (e) a high CD8⁺/FoxP3⁺ ratio (f) in ovarian-derived tumor tissue. Furthermore, FoxP3⁺ (g) and CD45R0⁺ T-lymphocytes (h) in omental metastases were associated with improved disease-specific survival